Overview
Sekisui Diagnostics develops, manufactures, and supplies clinical chemistry reagents, point-of-care tests, and pre-analytic systems for laboratories, hospitals, and healthcare providers worldwide. Their portfolio includes over 65 reagents for cardiovascular, diabetes, renal, and infectious disease testing, alongside rapid antigen and molecular tests like OSOM and Metrix for COVID-19, influenza, and respiratory health. They also provide specialty enzymes and materials for biotherapeutic manufacture, pharmaceutical production, and diagnostic reagents to support R&D and scale-up processes.
Frequently asked questions
- What diagnostic products does Sekisui Diagnostics offer for pharma and labs?
- Sekisui Diagnostics offers clinical chemistry reagents (>65 assays for cardiovascular, diabetes, renal, liver), point-of-care tests (OSOM rapid antigen, Metrix molecular for COVID/Flu), pre-analytic blood collection systems, and specialty enzymes for diagnostic and pharmaceutical manufacturing.
- What are the regulatory approvals for Sekisui's point-of-care tests?
- Products include CLIA-waived rapid tests with results in 10-30 minutes, high sensitivity/specificity; Metrix COVID/Flu is for point-of-care and home use; OSOM and Acucy brands serve professional and OTC markets.
- What geographies does Sekisui Diagnostics serve?
- Sekisui Diagnostics operates globally, supplying diagnostics to physicians, hospitals, labs, and alternate sites worldwide, with over 1.8 billion tests performed annually using their products.